📰 ET Markets 🔴 BEARISH 🕒 26 Oct 2026, 11:49 PM IST

Dalmia Bharat posts Rs 205 crore Q2 loss on exceptional hit

⚡ Instant Key Takeaways (TL;DR)

🎯

Core Development: Dalmia Bharat posts Rs 205 crore Q2 loss on exceptional hit

📊

Market & Financial Impact: Dalmia Bharat experienced a consolidated loss of Rs 205 crore in the September quarter of this year. This loss was due to an exceptional hit of Rs 339 crore related to asset impairment and employee separation. Sales volume rose by 3% year-on-year, while consolidated revenue increased by 4% to Rs 3,563 crore. However, EBITDA fell by 29% due to rising power and fuel costs, which increased by 22%.

💡

Actionable Insight: 🔴 Bearish Risk: Regulatory scrutiny, profit decline, or sell-off risk may create near-term volatility.

Power and fuel costs weigh on margins despite higher sales volumes and revenue

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

Will oil turn into a lingering problem? Is the world economy, India, or the market prepared?

KYB and KYC: Business behind the wealth creator called ‘Divi’s Lab’ – Part 2, concluding

📰

Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.

Read Original Full Coverage on Economic Times ↗

⚡

Get Breaking Stock Alerts & Q-Results on Telegram

Real-time 1200x675 image cards and financial filings delivered instantly.

Join @Zerolive_news ↗

Dalmia Bharat posts Rs 205 crore Q2 loss on exceptional hit

🔥 More Live Market Stories

McDonald’s new bet on chicken hits a snag as franchisees say the birds are too big

Intuitive Surgical SVP Patricia Wadors sells $478,416 in shares

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

River City Bank Q3 2026 slides: core earnings rise, credit quality pristine

Fed hold expected this week as markets watch for December hike signals

Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on